Are you Dr. James?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 41 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3855 Health Sciences Dr # 820
Ucsd Moore's Cancer Center
La Jolla, CA 92093Phone+1 858-822-7894Fax+1 858-534-5620- Is this information wrong?
Summary
- Dr. Danelle James, MD is an oncologist in La Jolla, California. She is currently licensed to practice medicine in California.
Education & Training
- University of California (San Diego) Medical CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
- University of California (San Diego) Medical CenterResidency, Internal Medicine, 2002 - 2005
- Pennsylvania State University College of MedicineClass of 2002
Certifications & Licensure
- CA State Medical License 2004 - 2025
Clinical Trials
- Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2008 Feb 01
- Ofatumumab and High-dose Methylprednisolone in Patients With Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2010 Aug 01
- Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2010 Aug 01
Publications & Presentations
PubMed
- 78 citationsIbrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized...William G. Wierda, John N. Allan, Tanya Siddiqi, Thomas J. Kipps, Stephen Opat, Alessandra Tedeschi, Xavier C. Badoux, Bryone J. Kuss, Sharon Jackson, Carol Moreno, Ry...> ;Journal of Clinical Oncology. 2021 Oct 7
- 18 citationsImpact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia.Isabelle G. Solman, Lisa K. Blum, Jan A. Burger, Thomas J. Kipps, James P. Dean, Danelle F. James, Ann Mongan> ;Leukemia Research. 2021 Feb 5
- 58 citationsIbrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study.Margaret A. Tempero, D-Y. Oh, J. Tabernero, Michele Reni, E. Van Cutsem, Andrew Eugene Hendifar, Dirk Waldschmidt, Naureen Starling, J-B. Bachet, H-M. Chang, Juan Maur...> ;Annals of Oncology. 2021 Feb 1
- Join now to see all
Press Mentions
- Results from IMBRUVICA® (Ibrutinib) RESONATE-2 Study Provide up to Seven Years of Progression-Free and Overall Survival Data in First-Line Chronic Lymphocytic Leukemia (CLL)June 4th, 2021
- “Collaboration Is Key.” with Danelle JamesDecember 9th, 2020
- AbbVie Submits Supplemental New Drug Application to U.S. FDA for IMBRUVICA® (Ibrutinib) in Combination with Rituximab for the Treatment of Previously Untreated, Younger Adults with Chronic Lymphocytic LeukemiaDecember 23rd, 2019
- Join now to see all
Professional Memberships
- Member